Gain Therapeutics, Inc. (GANX)
| Market Cap | n/a |
| Revenue (ttm) | 28,881 |
| Net Income (ttm) | -3.58M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
News
Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, filed on Friday with the SEC to raise up to $40 million in an initial public offer...
Gain Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
About GANX
Gain Therapeutics is a development stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (“LSDs”), including rare genetic diseases and neurological disorders. We use our exclusively in-licensed proprietary platform, Site-Directed Enzyme Enhancement Therapy (“SEE-Tx”), to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treatin... [Read more...]
| Industry Pharmaceutical Preparations | IPO Date Pending |
| CEO Eric I. Richman | Employees 11 |
| Stock Exchange NASDAQ | Ticker Symbol GANX |
Financial Performance
In 2020, GANX's revenue was $28,881, a decrease of -30.07% compared to the previous year's $41,301. Losses were -$3.58 million, 63.1% more than in 2019.